Quantification of the effects of an alpha-2 adrenergic agonist on reflex properties in spinal cord injury using a system identification technique

Journal of NeuroEngineering and Rehabilitation

Volumn 7, Issue 1, 2010, Pages

  Mirbagheri, Mehdi M ^a,b   Chen, David ^a,b   Rymer, W Zev ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b REHABILITATION INSTITUTE OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; DRUG DERIVATIVE; RECEPTOR, ADRENERGIC, ALPHA 2A; RECEPTOR, ADRENERGIC, ALPHA-2A; TIZANIDINE;

ADULT; ANKLE; ARTICLE; DRUG EFFECT; DRUG POTENTIATION; ELASTICITY; HUMAN; JOINT CHARACTERISTICS AND FUNCTIONS; PATHOPHYSIOLOGY; PHYSIOLOGY; REFLEX; SKELETAL MUSCLE; SPASTICITY; SPINAL CORD INJURY; STIMULATION; TORQUE;

ADRENERGIC ALPHA-AGONISTS; ADULT; ANKLE JOINT; CLONIDINE; ELASTICITY; HUMANS; MUSCLE SPASTICITY; MUSCLE, SKELETAL; PHYSICAL STIMULATION; RANGE OF MOTION, ARTICULAR; RECEPTORS, ADRENERGIC, ALPHA-2; REFLEX; SPINAL CORD INJURIES; TORQUE;

EID: 77953716497     PISSN: None     EISSN: 17430003     Source Type: Journal    
DOI: 10.1186/1743-0003-7-29     Document Type: Article

References (41)

1. Long-term survival and causes of death. MJ DeVivo SL Stover, Spinal Cord Injury: Clinical Outcomes from the Model Systems Aspen: Gaithersburg, Stover SL, DeLisa JA, Whiteneck GG, 1995
2. The economic impact of spinal cord injury. MJ DeVivo GG Whiteneck ED Charles, Spinal Cord Injury: Clinical Outcomes from the Model Systems Aspen: Gaithersburg, Stover SL, DeLisa JA, Whiteneck GG, 1995
3. Clinical syndromes associated with disproportionate weakness of the upper versus the lower extremities after cervical spinal cord injury. AD Levi CH Tator RP Bunge, Neurosurgery 1996 38 79 83 10.1097/00006123-199601000-00039 (Pubitemid 26002397)
4. Disordered muscle tone. J Lance J McLeod, Physiological Approach to Clinical Neurology Boston: Butterworths 1981
5. Spastic hypertonia: Mechanisms and measurement. RT Katz WZ Rymer, Arch Phys Med Rehabil 1989 70 144 155 2644919
6. Tizanidine vs baclofen in the treatment of spasticity in patients with multiple sclerosis. B Bass B Weinshenker GP Rice JH Noseworthy MG Cameron W Hader S Bouchard GC Ebers, Can J Neurol Sci 1988 15 15 19 3345456
7. Treatments for spasticity and pain multiple sclerosis: a systematic review. S Beard A Hunn J Wight, Health Technol Asses 2003 7 40 1 111 iii, ix, x
8. Comparative efficacy and saftey of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. R Chou K Peterson M Helfand, J Pain Symptom Manag 2004 28 2 140 147 10.1016/j. jpainsymman.2004.05.002 (Pubitemid 38970077)
9. The guidelines for the diagnosis and treatment of spasticity. I Dones V Nazzi G Broggi, J Neruosurg Sci 2006 50 4 101 105
10. Traditional pharmacological treatments for spsticity. Part II: General and regional treatments. JM Gracies P Nance E Elovic J McGuire DM Simpson, Muscle Nerve Suppl 1997 6 92 120 10.1002/(SICI)1097-4598(1997)6+<92::AID- MUS7>3.0.CO;2-E 9826984
11. Tizanidine vs baclofen in the treatment of spasticity in multiple sclerosis patients. MC Hoogstraten RJ van der Ploeg W vd Burg A Vreeling S van Marle JM Minderhoud, Acta Neurol Scand 1988 77 224 230 10.1111/j.1600-0404.1988. tb05899.x 3376747
12. Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review. E Montane A Vallano JR Laporte, Neurology 2004 63 8 1357 1363 15505149
13. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. AJ Wagstaff HM Bryson, Drugs 1997 53 3 435 452 10.2165/00003495- 199753030-00007 9074844
14. Effects of monoamines on transmission from group II muscle afferents in sacral segments in the cat. E Jankowska ZS Lackberg LE Dyrehag, Eur J Neurosci 1994 6 6 1058 1061 10.1111/j.1460-9568.1994.tb00601.x 7952276 (Pubitemid 24185330)
15. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Anonymous, Neurol 1994 44 suppl 9 70 S78
16. Tizanidine in the management of spasticity and musculoskeletal complaints in the palliative care population. HS Smith AE Barton, J Hospice Palliative Care 2000 17 1 50 58 10.1177/104990910001700111
17. Summary of combined clinical analysis of contolled clinical trials with tizanidine. JD Wallace, Neurol 1994 44 suppl 9 60 S69
18. A double-blind comparative trial of a new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. C Smolenski S Muff S Smolenski-Kautz, Curr Med Res Opin 1981 7 374 383 7016449
19. Neuropharmacology and mechanism of action. DM Coward, Neurol 1994 44 suppl 9 6 S11
20. Effects of intrathecal alpha1- and alpha2-noradrenergic agonists and norepinephrine on locomotion in chronic spinal cats. C Chau H Barbeau S Rossignol, Journal of Neurophysiology 1998 79 6 2941 2963 9636099
21. Electrophysiological analysis of mode of action of muscle relaxants in spasticity. P Delwaide, Ann Neurol 1985 17 90 95 10.1002/ana.410170119 3985591
22. Cutaneous depression of Ib reflex pathways to motoneurons in man. E Pierrot-Deseilligny E Bergego R Katz C Morin, Exp Brain Res 1981 42 351 361 7238675
23. Distribution of alpha2 agonist binding sites in the rat and human central nervous system: analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents. JR Unnerstall TA Kopajtic MJ Kuhar, Brain Res 1984 319 69 101 6324960
24. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. PW Nance J Bugaresti K Shellenberger W Sheremata A Martinez-Arizala Group NATS, Neurol 1994 44 suppl 9 44 S52
25. Review of clinical trials with tizanidine (Sirdalud). M Emre, Spasticity: the current status of reserach and treatment Lancashire, UK: Parthenon, Emre M, Benecke R, 1989 153 184
26. Antiparetic and antispastic effects induced by tizanidne in pateints with spastic paresis. E Knutsson A Martensson L Gronsberg, J Neuro Sci 1982 53 187 204 10.1016/0022-510X(82)90005-3 (Pubitemid 12223940)
27. Comparative profile of tizanidine in the management of spastictiy. X Lataste M Emre C Davis L Groves, Neurol 1994 44 suppl 9 53 S59
28. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. CJ Mathias J Luckitt P Desai H Baker W el Masri HL Frankel, J Rehabil Res Dev 1989 26 9 16 2600869
29. Muscle and reflex changes with varying joint angle in hemiparetic stroke. MM Mirbagheri L Alibiglou M Thajchayapong WZ Rymer, J Neuroeng Rehabil 2008 27 5 1 15
30. Intrinsic and reflex stiffness in normal and spastic spinal cord injured subjects. MM Mirbagheri M Ladouceur H Barbeau RE Kearney, Exp Brain Res 2001 141 446 459 10.1007/s00221-001-0901-z 11810139
31. Neuromuscular abnormalities associated with spasticity of upper extremity muscles in hemiparetic stroke. MM Mirbagheri K Settle R Harvey WZ Rymer, J Neurophysiol 2007 98 2 629 637 10.1152/jn.00049.2007 17537910
32. Intrinsic and reflex contributions to human ankle stiffness: Variation with activation level and position. MM Mirbagheri H Barbeau RE Kearney, Exp Brain Res 2000 135 423 436 10.1007/s002210000534 11156307
33. Preliminary trial of carisoprodol in multiple sclerosis. B Ashworth, Practitioner 1964 192 540 542 14143329
34. Inter-rater reliability on a modified Ashworth scale of muscle spasticity. RW Bohannon MB Smith, Phys Ther 1987 67 206 207 3809245
35. Identification of intrinsic and reflex contributions to human ankle stiffness dynamics. RE Kearney RB Stein L Parameswaran, IEEE Trans Biomed Eng 1997 44 493 504 10.1109/10.581944 9151483
36. Mediation of late excitation from human hand muscles via parallel group II spinal and group I transcortical pathways. G Lourenco C Lglesias P Cavallari E Pierrot-Deseilligny V Marchand-Pauvert, J Phys 2006 572 Pt 2 585 603
37. Afferent-mediated modulation of the soleus muscle activity during the stance phase of human walking. N Mazzaro MJ Grey OF do Nascimento T Sinkjaer, Exp Brain Res 2006 173 4 713 723 10.1007/s00221-006-0451-5 16639501
38. The relation between Ashworth scores and neuromechanical measurements of spasticity following stroke. L Alibiglou WZ Rymer RL Harvey MM Mirbagheri, J Neuroeng Rehabil 2008 5 18 1 14 18171465
39. System identification of human joint dynamics. RE Kearney IW Hunter, Crit Rev Biomed Eng 1990 18 1 55 87 2204515
40. The effects of long-term FES-assisted walking on intrinsic and reflex dynamic stiffness in spastic SCI subjects. MM Mirbagheri M Ladouceur H Barbearu KR E, IEEE Trans Neural System Rehabil Eng 2002 10 4 280 289 10.1109/TNSRE.2002.806838 (Pubitemid 36207322)
41. Pharmacology and mechanisms of action of tizanidine (Sirdalud). DM Coward, Spasticity: the current status of reserach and treatment New trends in clinical neruology series Lancashire, UK: Parthenon, Emre M, Benecke R, 1989 131 140